Does Wellcare Cover Forteo?
The verdict
Conditional on most plans
Wellcare (Centene) covers teriparatide for severe osteoporosis, but brand Forteo is frequently non-preferred — plan drug lists and state Medicaid PDLs generally designate generic teriparatide injection or Bonsity as the preferred option. When approved, teriparatide is a specialty drug requiring prior authorization of 12–24 months and documented bisphosphonate trial or failure. On Part D, the $2,100 (2026) cap limits annual cost exposure; on Medicaid, cost-share is nominal. Because Wellcare is a Centene Medicare Part D and Medicaid managed-care operation, coverage specifics vary by state PDL — verify on your Wellcare plan drug list.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Wellcare using your member ID.
Key facts
Brand Forteo is widely flagged as 'typically excluded from coverage' across major insurers — generic teriparatide injection and Bonsity are the preferred alternatives on most Medicare Part D formularies and state Medicaid PDLs.
CMS formulary guidance; KFF Medicare Part D specialty drug coverage analysis
Manufacturer copay assistance (Lilly Cares) is not available to Medicare or Medicaid beneficiaries — the $2,100 (2026) Part D annual cap is the primary cost protection for Wellcare Medicare members on teriparatide.
Eli Lilly patient assistance program terms; CMS 2026 Part D benefit parameters
Wellcare is operated by Centene, which manages Medicaid PDLs across many states — teriparatide preferred-drug status for brand Forteo versus generic varies by state PDL.
Centene Corporation coverage documentation; state Medicaid PDL resources
Medicare vs. commercial coverage
Whether Wellcare covers Forteo depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Medicare Part D (operative pathway): teriparatide is on the specialty tier with PA (12–24 months) and step therapy through the preferred generic teriparatide injection or Bonsity before brand Forteo. Brand Forteo is frequently non-preferred or requires an additional exception on Wellcare Part D formularies. When teriparatide is approved, the member pays 25–33% coinsurance after the deductible; the $2,100 (2026) Part D out-of-pocket cap limits annual exposure. The manufacturer's patient-assistance program (Lilly Cares) is NOT available to Medicare beneficiaries under federal anti-kickback rules. Verify the specific formulary status of brand Forteo versus generic teriparatide on your Wellcare plan drug list.
Commercial / Employer
Group & marketplace plans
Commercial/Employer: Wellcare has minimal commercial presence; teriparatide coverage follows specialty-tier PA rules where it exists; brand Forteo often non-preferred. ACA/Individual: limited; teriparatide covered with PA where offered; brand Forteo often non-preferred. Medicaid: Wellcare-managed Medicaid (Centene) covers teriparatide per state preferred drug list; generic teriparatide or Bonsity is typically preferred over brand Forteo per state PDL; nominal cost-share ($0–$4). Because Centene operates across many state Medicaid PDLs, preferred-drug status for brand Forteo versus generic teriparatide varies by state — verify on your state Wellcare Medicaid drug list or contact Wellcare member services.
The 3 boxes you must tick to get approved
Commercial plans that will consider Forteo require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
Meet all 3 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Forteo actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
Brand Forteo is a high-cost specialty drug — list price is several thousand dollars per month (estimate; verify current pricing). Generic teriparatide and Bonsity are lower-cost preferred alternatives (estimate).
List price with no coverage — before any manufacturer savings card.
With coverage
Medicare Part D: 25–33% coinsurance on the specialty tier after the deductible; the $2,100 (2026) annual cap limits exposure. Medicaid: $0–$4 nominal cost-share per state PDL for approved teriparatide (typically the generic). Dual-eligible members' Part D cost-share may be covered by Medicaid.
Typical monthly copay once prior authorization is approved.
Bridge program
Lilly Cares Foundation patient assistance may be available to commercially insured patients. Medicare and Medicaid beneficiaries are NOT eligible for manufacturer copay support under federal anti-kickback rules. Verify eligibility with Eli Lilly directly.
Reduced copay through the assistance program, where eligible.
All figures are estimates. Actual cost-share depends on your specific Wellcare plan and state PDL. Verify your cost-share on your Wellcare plan drug list or by calling Wellcare member services.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Check your Wellcare plan drug list or state Medicaid PDL
Log in to your Wellcare member account or visit your state's Medicaid preferred drug list to look up teriparatide (Forteo, Bonsity, or generic teriparatide). Brand Forteo and generic teriparatide may have different tier placements and coverage criteria. Confirm which version is preferred or covered on your specific plan before your prescriber submits a PA.
- 2
Have your prescriber submit prior authorization with full documentation
Ask your prescribing physician to submit a PA that includes your DEXA scan results (or fracture history), FRAX score if available, and documentation of prior bisphosphonate trial or intolerance. If brand Forteo is requested but a preferred generic is available, your prescriber should include a medical necessity justification for the brand. PA approval typically takes a few business days to two weeks.
- 3
Confirm your Part D cap exposure or Medicaid cost-share
If you have Wellcare Medicare Part D, confirm that the $2,100 (2026) annual out-of-pocket cap applies to your approved teriparatide. Once you reach that cap, you pay $0 for covered Part D drugs for the rest of the calendar year. If you have Wellcare Medicaid, your cost-share is typically nominal ($0–$4 per fill) — verify on your state's Wellcare Medicaid plan documents.
Options if Wellcare won't cover Forteo
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Generic teriparatide injection
The preferred alternative to brand Forteo on most Wellcare Part D formularies and state Medicaid PDLs — same PTH-analog molecule, same daily subcutaneous injection, typically at a lower tier and cost-share. Requires the same PA and bisphosphonate-failure documentation.
Bonsity (teriparatide-tjwp)
FDA-approved teriparatide biosimilar often preferred over brand Forteo. Listed at a lower tier on many formularies. Same mechanism, same injection schedule; PA and clinical documentation required.
Prolia (denosumab) / Jubbonti
Medical-benefit q6-month clinic injection covered under Medicare Part B for most Wellcare Medicare members — a different drug class, benefit rail, and dosing schedule compared to Forteo. For dual-eligible Wellcare members, Medicaid may cover the Part B coinsurance, often reducing out-of-pocket to $0. Discuss with your prescriber which is clinically appropriate.
Oral bisphosphonates (generic alendronate, risedronate)
Typically required as a prior therapy step before teriparatide is approved. Generic bisphosphonates are Tier 1–2 on most Wellcare formularies at minimal cost-share. If you have failed or are intolerant of bisphosphonates, document this for the teriparatide PA.
These options are listed for information only — your own clinician decides what is appropriate for you.
❓Frequently Asked Questions
Brand Forteo is frequently non-preferred on Wellcare Medicare Part D formularies — generic teriparatide injection or Bonsity is typically the preferred option. You may be approved for the generic rather than brand Forteo. Verify on your specific Wellcare plan drug list. If your prescriber has a documented clinical reason you need the brand specifically, a medical exception can be requested through the PA process.
Yes, Wellcare-managed Medicaid (Centene) covers teriparatide for severe osteoporosis per state preferred drug lists, typically with prior authorization and documented bisphosphonate trial or failure. Generic teriparatide or Bonsity is usually preferred over brand Forteo on state PDLs. Cost-share is nominal ($0–$4) on Medicaid. Because Centene operates across many states, specific PDL preferred-drug status for brand Forteo versus generic varies — verify on your state's Wellcare Medicaid drug list.
Wellcare Part D and Medicaid plans typically require documented severe osteoporosis (T-score at or below -2.5 or fragility fracture) and prior failure or intolerance of a bisphosphonate. Your prescriber submits the PA including DEXA scan results, fracture history, and prior treatment documentation. PA approval is usually 12–24 months and requires renewal with continued clinical documentation.
No, if you are enrolled in Wellcare Medicare or Medicaid. Federal anti-kickback rules prohibit Medicare and Medicaid beneficiaries from using manufacturer copay assistance programs, including Lilly's Forteo support. Most Wellcare members are on Medicare or Medicaid and cannot use these programs. The Part D $2,100 annual cap is the primary cost-protection mechanism for Medicare beneficiaries on teriparatide.
Yes. If teriparatide is covered on your Wellcare Medicare Part D plan, the $2,100 (2026) annual out-of-pocket cap applies. Once you reach that cap for the year, you pay $0 for all covered Part D drugs for the rest of the calendar year. Teriparatide is a high-cost specialty drug, so this cap is meaningful — confirm your plan's OOP structure with Wellcare member services.
Related Articles
Does Aetna Cover Vyvanse? 2026 CVS Caremark Formulary
Aetna covers Vyvanse via CVS Caremark — generic lisdexamfetamine preferred, brand non-preferred. 70 mg/day QL per Policy 5.60.024; age-22 PA required.
Read moreDoes Aetna Cover Prolia? CVS Caremark Medical Benefit | Curex
Aetna covers Prolia under the medical benefit with PA — a q6-month clinic injection, not Part D. Jubbonti biosimilar now preferred on CVS Caremark.
Read moreDoes Anthem Cover Adderall? 2026 Coverage Guide | Curex
Anthem covers Adderall through CarelonRx — generic preferred, brand non-preferred. Step therapy may apply on some plans. Verify your Anthem plan.
Read moreDoes Anthem Cover Contrave? 2026 Brand Coverage Guide | Curex
Anthem covers Contrave only if your plan has a weight-loss benefit. Many plans carve it out. CurAccess ~$99/mo is often the fastest path.
Read moreDoes Aetna Cover Contrave? 2026 CVS Caremark Guide | Curex
Aetna (CVS Caremark) often excludes Contrave under AOM carve-outs. Where covered, CVS BMI prior auth applies. Medicare bars it by law. CurAccess ~$99/mo.
Read moreDoes Aetna Cover Forteo? 2026 Coverage Guide
Aetna (CVS) often excludes brand Forteo in favor of generic teriparatide or Bonsity. Teriparatide is covered with PA and bisphosphonate step therapy. 2026.
Read moreThis content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Wellcare before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation.